Chennai: An immunologist, who had studied her PG in Oxford University, has claimed to have come out with a research recommending a monoclonal antibody drug that would prevent
inflammation and deaths among Covid patients.
Gowthami Balasubramanian, who had her post-graduation in M.Sc–Integrated Immunology from the University of Oxford, England, said during her specialised research in inflammatory
Autoimmune Disorder at University of Oxford, she derived a drug which was approved by the Department of Oncology, Oxford University.
The result has been found to be relevant in tackling Covid-19. Her monoclonal antibody drug recommendation based on these results will drastically prevent inflammation during the final stages of the disease, provide relief and prevent death.
“This is not a vaccine, but only a medicine to prevent the death of patients who are in a critical condition,” she said and wanted the Tamilnadu government to take her research findings to the next level for the benefit of Covid patients.